41.74 USD
▼-0.90-2.11%
盘后 49.20 0.00%
2026-09-15
市值
$2.13B
市盈率
—
EPS
-1.97
股息率
—
52 周区间
15.86 – 50.81
成交量
545.78K
Beta
1.58
目标价
60.00
52W 低 15.8652W 高 50.81
价格走势
公司简介
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocal...